Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
RESMED INC
Report date May 04, 2026 · Filed May 04, 2026
Section 16 reporting ended · disclosed 2026-05-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| ResMed Common StockSEC Table I · non-derivative | Direct | 83,495 |
Reported balance
Holding disclosure · report date 2026-05-04 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 83,495 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2018 Filed Jan 4, 2018 16:52 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,250 | $84.99 | $106,237.50 |
DisclosureSEC source: 0001140361-18-000685 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,322 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 21:37 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,250 | $85.36 | $106,700.00 |
DisclosureSEC source: 0001140361-17-044862 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,572 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| November 27, 2017 Filed Nov 28, 2017 23:30 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 8,920 | $84.63 | $754,899.60 |
DisclosureSEC source: 0001140361-17-044018 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,822 F1 · kind: Shares acquired on vesting of performance-based restricted stock units. The PSUs were granted November 19, 2014, with a three-year performance period. The shares were earned and vested November 27, 2017, when the ResMed compensation committee certified performance. F2 · shares: Shares earned based on performance at 57% of the target award. Read SEC document |
| November 01, 2017 Filed Nov 2, 2017 23:12 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,250 | $84.50 | $105,625.00 |
DisclosureSEC source: 0001140361-17-040829 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,772 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| October 10, 2017 Filed Oct 12, 2017 19:47 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 4,301 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-038521 · doc1.xml · nonDerivative · entry 2 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,022 F2 · shares: Represents performance-based restricted stock units granted on November 16, 2016. The shares were earned on October 10, 2017, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| October 10, 2017 Filed Oct 12, 2017 19:47 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 4,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-038521 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,721 F1 · shares: Represents performance-based restricted stock units granted on November 19, 2015. The shares were earned on October 10, 2017, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| October 02, 2017 Filed Oct 3, 2017 21:54 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,250 | $77.05 | $96,312.50 |
DisclosureSEC source: 0001140361-17-037427 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,691 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 15:45 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,250 | $77.56 | $96,950.00 |
DisclosureSEC source: 0001140361-17-034230 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,941 F1 · kind: The transaction was conducted under a Rule10b5-1 Plan. Read SEC document |
| August 17, 2017 Filed Aug 21, 2017 15:23 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 7,933 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-032790 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,191 F1 · shares: Represents performance-based restricted stock units granted on November 16, 2016. The shares were earned on August 17, 2017, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 01, 2017 Filed Aug 2, 2017 01:16 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,250 | $77.49 | $96,862.50 |
DisclosureSEC source: 0001140361-17-029733 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,258 F1 · kind: The transaction was conducted under a Rule10b5-1 Plan. Read SEC document |
| July 03, 2017 Filed Jul 5, 2017 22:56 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,250 | $77.44 | $96,800.00 |
DisclosureSEC source: 0001140361-17-027222 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,508 F1 · kind: The transaction was conducted under a Rule10b5-1 Plan. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 17:12 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,250 | $71.02 | $88,775.00 |
DisclosureSEC source: 0001140361-17-023731 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,758 F1 · kind: The transaction was conducted under a Rule10b5-1 Plan. F2 · balance_after: Includes 225 shares of ResMed stock purchased on April 28, 2017, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| May 01, 2017 Filed May 3, 2017 17:25 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,250 | $68.60 | $85,750.00 |
DisclosureSEC source: 0001140361-17-018050 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,783 F1 · kind: The transaction was conducted under a Rule10b5-1 Plan. Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 23:52 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,250 | $71.65 | $89,562.50 |
DisclosureSEC source: 0001140361-17-014718 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,033 F1 · kind: The transaction was conducted under a Rule10b5-1 Plan. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 02:57 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,250 | $72.48 | $90,600.00 |
DisclosureSEC source: 0001140361-17-010395 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,283 F1 · kind: The transaction was conducted under a Rule10b5-1 Plan. Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 01:52 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock Options · Derivative | 40,736 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001140361-16-087148 · doc1.xml · derivative · entry 2 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,736 Underlying: ResMed Common Stock · 40,736 shares Expires 2023-11-16 F2 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2017, 2018 and 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.